Plus Therapeutics, Inc.
4200 Marathon Blvd., Suite 200
Austin, TX 78756
September 19, 2019
VIA EDGAR
Michael Fay
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
|
Re: |
Plus Therapeutics, Inc. |
|
|
Registration Statement on Form S-1 |
|
|
Filed February 1, 2019 |
|
|
File No. 333-229485 |
Dear Mr. Fay:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Plus Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S‑1 referred to above be accelerated so that it will become effective at 12:00 P.M. Eastern Time on September 23, 2019, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Cheston J. Larson, Esq. of Latham & Watkins LLP at (858) 523-5435. Thank you for your assistance and cooperation in this matter.
Very truly yours,
PLUS THERAPEUTICS, INC.
|
By: |
/s/ Marc H. Hedrick, M.D. |
|
|
Marc H. Hedrick, M.D. |
|
|
President and Chief Executive Officer |
cc:Cheston J. Larson, Esq., Latham & Watkins LLP
Christopher G. Geissinger, Esq., Latham & Watkins LLP